Summary

Eligibility
for people ages 12 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Sue S Yom, MD (ucsf)
Headshot of Sue S Yom
Sue S Yom

Description

Summary

This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.

Official Title

Single-Arm Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants

Details

The primary objective of this study is to evaluate the efficacy of toripalimab in combination with chemotherapy (cisplatin and gemcitabine), as measured by objective response rate (ORR) assessed by a Blinded Independent Central Review Committee (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in first-line recurrent metastatic nasopharyngeal cancer participants (both Epstein-Barr virus (EBV) and non-EBV-associated).

Keywords

Nasopharyngeal Cancer Recurrent, Programmed death 1 [PD1] inhibitor, Toripalimab, Recurrent metastatic nasopharyngeal cancer, Nasopharyngeal Neoplasms, Nasopharyngeal Carcinoma, Recurrence, Carboplatin, Gemcitabine, Cisplatin

Eligibility

You can join if…

Open to people ages 12 years and up

  • Histological or cytological confirmation of recurrent/metastatic nasopharyngeal cancer with either EBV or non-EBV-associated cancer. The following subgroups are included:
    • EBER/EBV-negative (HPV+/-)
    • EBER/EBV-positive (HPV+/-)
  • Recurrent/metastatic (stage IV-B as defined by the International Union against Cancer [UICC] and American Joint Committee on Cancer [AJCC] staging system for nasopharyngeal cancer [NPC], eighth edition) or recurrent NPC after curative treatment. For recurrent NPC, more than 6 months between the last dose of radiotherapy or chemotherapy and the date of recurrence.
  • Measurable disease based on RECIST v 1.1 as determined by the site. Note: Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

You CAN'T join if...

  • Disease that is suitable for local therapy administered with curative intent.
  • Prior systemic therapy administered in the recurrent or metastatic setting. Participants who develop disease recurrence within 6 months from curative intent chemoradiation will be excluded.
  • Rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.
  • Active or untreated central nervous system (CNS) metastases (e.g., brain or leptomeningeal), as determined on computerized tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments. Participants who have prior therapies for brain or leptomeningeal metastasis and have been stabilized ≥ 1 month and have discontinued systemic steroid therapy (>10 mg/day prednisone or equivalent) ≥ 1 month prior to enrollment are eligible.

Other protocol-defined inclusion and exclusion criteria apply.

Location

  • University of California, San Francisco accepting new patients
    San Francisco California 94115 United States

Lead Scientist at University of California Health

  • Sue S Yom, MD (ucsf)
    I am a radiation oncologist who specializes in the treatment of head and neck, lung, and skin cancers. I serve on national guidelines committees outlining the best practices for these cancers. I design clinical trials to improve treatment of these cancers. I give lectures and design courses to help others learn more about how to best treat these cancers.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Coherus Biosciences, Inc.
ID
NCT06457503
Phase
Phase 4 Nasopharyngeal Cancer Research Study
Study Type
Interventional
Participants
Expecting 100 study participants
Last Updated